Aortic DiseasesAORTUSNCT04180553
Ultrasound-Guided Resuscitation in Open Aortic Surgery
A study testing Point of Care Ultrasound (POCUS) in people with Aortic Diseases, run by London Health Sciences Centre at 1 site in Canada.
Trial summary
This study will aim to determine whether routine Point of Care Ultrasound (POCUS) assessment of volume status, cardiac function, and pulmonary function after major abdominal aortic surgery is an accurate and feasible form of monitoring for individualized, goal-directed resuscitation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aortic Diseases
- What is being tested?
- Point of Care Ultrasound (POCUS)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 15 Jan 2020to 30 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must be 18 years of age or older.
- o There is no upper age limit for eligibility in this study.
- Elective surgical procedures
- Patients who are enrolled must be receiving open abdominal surgery for either occlusive disease (aortobifemoral bypass, transaortic endarterectomy) or aneurysmal disease (infrarenal, juxtarenal abdominal aortic aneurysms).
- Patients must be deemed suitable operative candidates for open abdominal aortic surgery as decided upon by the surgical and perioperative medicine assessments.
Who cannot join
- Thoracoabdominal aneurysms (Type IV or larger extent)
- Hybrid procedures (Requiring both endovascular and open surgical reconstruction)
- Pediatric vascular cases (Patients less than 18 years of age)
- Emergency cases
- American Society of Anesthesia (ASA) class 5 identified
- Chronic renal failure requiring dialysis
- Inability of patient to consent to study
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
London Health Sciences Center - Victoria Hospital
London, Ontario, N6A5W9
John Landau, MD, 5198524464, john.landau@londonhospitals.ca
About this study
This study will aim to determine whether routine Point of Care Ultrasound (POCUS) assessment of volume status, cardiac function, and pulmonary function after major abdominal aortic surgery is an accurate and feasible form of monitoring for individualized, goal-directed resuscitation. Half of the patients will receive POCUS-guided fluid resuscitation, and the other half will be resuscitated using usual post-operative care.
Read the detailed description
Patients assessed for elective open aortic surgery for both aneurysmal and occlusive disease either as inpatients or in the outpatient vascular surgery clinic will be screened for eligibility at the time of initial consultation. Once the patient has been screened for eligibility, the participant will be enrolled on the basis of informed consent with a letter of information. This study will be submitted for review by the Health Sciences Research Ethics Board at Western University. This will be a feasibility trial, with the primary endpoints reflecting safety and feasibility outcomes of executing the trial protocol as outlined in this document.
Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission, whereas the control group will be management by usual care for the first 48 hours of admission. Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and Inferior vena cava (IVC) study performed post-operatively in the surgery recovery room, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two.
The protocol for the intervention group will receive a 4-view transthoracic echocardiogram including the following views: Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis and subcostal 4-chamber if parasternal views are limited. Color Doppler will be used for qualitative valvular assessment if indicated. A longitudinal IVC view will be obtained in the usual subcostal transabdominal position, or the transhepatic position if the transabdominal view is not technically feasible. A thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. Participants randomized to the point of care ultrasound arm will also have access to routine avenues of patient assessment which include review of vital signs, biochemistry, and urine output as well as bedside physical exam. Images acquired will be overread by sonographic experts with expertise in bedside point of care echocardiography through a central image reporting system.
Point of care studies will synthesize cardiac, thoracic, and IVC views to elucidate whether patients who fluid deplete or fluid replete, and if ventricular dysfunction is contributing to hypotension or end-organ dysfunction. They will be allocated to either a fluid restrictive or fluid liberal management strategy accordingly. The fluid liberal group will receive a fluid infusion of 2ml/kg/hr of balanced crystalloid solution. For patients with a body weight greater than 100kg, fluid volumes will be calculated based on a maximum body weight of 100kg. The fluid restrictive group will receive a fluid infusion of 0.8ml/kg/hr of balanced crystalloid solution. IV boluses of crystalloid will be permitted to treat hypotension with systolic blood pressure <90 with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusions will be permitted to treat post-operative bleeding or anemia as clinically indicated. Those with severely decreased left ventricular function who are presumed to be hypotensive secondary to poor cardiac output will be transferred to an appropriate level 1 care monitored bed to receive vasopressors or inotropes to manage their hypotension. They will be managed to the fluid restrictive arm with an infusion rate of 0.8 ml/kg/hr of ringer's lactate solution. Once all patients are able to tolerate oral fluid intake, their maintenance IV fluid infusions will be discontinued.
Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
This protocol does not restrict formal radiographic or ultrasound studies such as plain film x-rays, CT, MRI, echocardiography, abdominal ultrasonography, and duplex ultrasound of lower extremity veins in patients in the intervention or control groups with appropriate clinical indications.
- Conditions
- Aortic Diseases
- Being tested
- Point of Care Ultrasound (POCUS), Usual Care
- Keywords
- Ultrasound, Goal-directed resuscitation
- Medical subject headings
- Aortic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Point of Care Ultrasound (POCUS)Diagnostic test
The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP <90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
Usual CareOther
The control group for "usual care" will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
| Study group | Role | What they receive |
|---|---|---|
| Point-Of-Care Ultrasound Guided Resuscitation | Experimental | Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment. Receives: Diagnostic Test: Point of Care Ultrasound (POCUS) |
| Usual Care | Active comparator | The comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria Receives: Other: Usual Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility - Recruitment
Recruitment - Overall proportion of eligible patients successfully entered into the study divided by the total number of eligible patients consented and retained to full data completion - ≥80% recruitment rate
Measured: 30 days
Feasibility - Successful Randomization
Overall proportion of consented patients successfully receiving randomization at the completion of operation divided by the total number of consented patients - ≥80% randomized
Measured: 30 days
Feasibility - POCUS Study completion
Overall proportion of completed studies divided by expected studies - ≥80% completion
Measured: 30 days
Feasibility - Protocol Adherence
Overall proportion of patients adequately receiving treatment as defined by the trial protocol divided by the total number of patients enrolled - ≥80% Adherence
Measured: 30 days
Feasibility - Successful Data Collection
Overall proportion of patients with no absent data points in the database divided by the total number of patients enrolled - ≥80% complete data sets
Measured: 30 days
Feasibility - Contamination rate
The number of patients crossed over into the opposite arm of the study based on patient or physician motivators divided by the total number of patients enrolled - ≤20% contamination
Measured: 30 days
Secondary outcomes (1)
Feasibility - POCUS image quality
Image quality - Agreement between physicians performing POCUS and experts auditing studies will be measured for both image acquisition and interpretation - ≥80% agreement
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2019
- Study start15 Jan 2020
- Primary completion30 Oct 2021 (estimated)
- Study completion30 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial - 20 patients per arm. A permuted block randomization plan will be used with block sizes of 2 and 4
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Luc Dubois, London Health Sciences Centre
- Investigators
- Luc Dubois, MD, Principal investigator, London Health Sciences Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04180553
- Sponsor's protocol ID
- 113875
- Acronym
- AORTUS
- Status last verified
- Feb 2021
- First submitted
- 22 Oct 2019
- Last updated
- 24 Feb 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: As this is a feasibility trial, there are no plans to make individual patient data available to other researchers. The individual patient data may be used as part of a larger randomized controlled trial if the feasibility trial shows the protocol is feasible and safe.
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-Guided Resuscitation in Open Aortic Surgery
- ClinicalTrials.gov ID
- NCT04180553
- Acronym / sponsor ID
- AORTUS / 113875
- Conditions
- Aortic Diseases
- Keywords
- Ultrasound, Goal-directed resuscitation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- London Health Sciences CentreUniversity, hospital or other
- Study start
- 15 Jan 2020 (actual)
- Primary completion
- 30 Oct 2021 (estimated)
- Study completion
- 30 Dec 2021 (estimated)
- First posted
- 27 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will aim to determine whether routine Point of Care Ultrasound (POCUS) assessment of volume status, cardiac function, and pulmonary function after major abdominal aortic surgery is an accurate and feasible form of monitoring for individualized, goal-directed resuscitation. Half of the patients will receive POCUS-guided fluid resuscitation, and the other half will be resuscitated using usual post-operative care.
Detailed description
Patients assessed for elective open aortic surgery for both aneurysmal and occlusive disease either as inpatients or in the outpatient vascular surgery clinic will be screened for eligibility at the time of initial consultation. Once the patient has been screened for eligibility, the participant will be enrolled on the basis of informed consent with a letter of information. This study will be submitted for review by the Health Sciences Research Ethics Board at Western University. This will be a feasibility trial, with the primary endpoints reflecting safety and feasibility outcomes of executing the trial protocol as outlined in this document.
Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission, whereas the control group will be management by usual care for the first 48 hours of admission. Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and Inferior vena cava (IVC) study performed post-operatively in the surgery recovery room, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two.
The protocol for the intervention group will receive a 4-view transthoracic echocardiogram including the following views: Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis and subcostal 4-chamber if parasternal views are limited. Color Doppler will be used for qualitative valvular assessment if indicated. A longitudinal IVC view will be obtained in the usual subcostal transabdominal position, or the transhepatic position if the transabdominal view is not technically feasible. A thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. Participants randomized to the point of care ultrasound arm will also have access to routine avenues of patient assessment which include review of vital signs, biochemistry, and urine output as well as bedside physical exam. Images acquired will be overread by sonographic experts with expertise in bedside point of care echocardiography through a central image reporting system.
Point of care studies will synthesize cardiac, thoracic, and IVC views to elucidate whether patients who fluid deplete or fluid replete, and if ventricular dysfunction is contributing to hypotension or end-organ dysfunction. They will be allocated to either a fluid restrictive or fluid liberal management strategy accordingly. The fluid liberal group will receive a fluid infusion of 2ml/kg/hr of balanced crystalloid solution. For patients with a body weight greater than 100kg, fluid volumes will be calculated based on a maximum body weight of 100kg. The fluid restrictive group will receive a fluid infusion of 0.8ml/kg/hr of balanced crystalloid solution. IV boluses of crystalloid will be permitted to treat hypotension with systolic blood pressure <90 with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusions will be permitted to treat post-operative bleeding or anemia as clinically indicated. Those with severely decreased left ventricular function who are presumed to be hypotensive secondary to poor cardiac output will be transferred to an appropriate level 1 care monitored bed to receive vasopressors or inotropes to manage their hypotension. They will be managed to the fluid restrictive arm with an infusion rate of 0.8 ml/kg/hr of ringer's lactate solution. Once all patients are able to tolerate oral fluid intake, their maintenance IV fluid infusions will be discontinued.
Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
This protocol does not restrict formal radiographic or ultrasound studies such as plain film x-rays, CT, MRI, echocardiography, abdominal ultrasonography, and duplex ultrasound of lower extremity veins in patients in the intervention or control groups with appropriate clinical indications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized controlled trial - 20 patients per arm. A permuted block randomization plan will be used with block sizes of 2 and 4
| Arm | Type | Receives |
|---|---|---|
| Point-Of-Care Ultrasound Guided Resuscitation | Experimental | Diagnostic Test: Point of Care Ultrasound (POCUS)Intervention in this trial is randomization to POCUS management for goal-directed post-operative resuscitation for the first 48 hours of admission.Patients randomized to the use of POCUS will have a focused cardiac, thoracic, and IVC study performed post-operatively in PACU, as well as regular (BID) assessments on the inpatient ward for post-operative day one and two. Based on ultrasound findings, their fluid resuscitation will be guided to a fluid liberal or fluid restrictive strategy at the time of each assessment. |
| Usual Care | Active comparator | Other: Usual CareThe comparator arm in this trial is randomization to usual care. Participants randomized to control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients must be 18 years of age or older.
- o There is no upper age limit for eligibility in this study.
- Elective surgical procedures
- Patients who are enrolled must be receiving open abdominal surgery for either occlusive disease (aortobifemoral bypass, transaortic endarterectomy) or aneurysmal disease (infrarenal, juxtarenal abdominal aortic aneurysms).
- Patients must be deemed suitable operative candidates for open abdominal aortic surgery as decided upon by the surgical and perioperative medicine assessments.
Key exclusion criteria (7 listed)
- Thoracoabdominal aneurysms (Type IV or larger extent)
- Hybrid procedures (Requiring both endovascular and open surgical reconstruction)
- Pediatric vascular cases (Patients less than 18 years of age)
- Emergency cases
- American Society of Anesthesia (ASA) class 5 identified
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Point of Care Ultrasound (POCUS)The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP <90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated. | Diagnostic test | Point-Of-Care Ultrasound Guided Resuscitation |
| Usual CareThe control group for "usual care" will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated. | Other | Usual Care |
Primary outcome
Feasibility - Recruitment
Time frame: 30 days
Recruitment - Overall proportion of eligible patients successfully entered into the study divided by the total number of eligible patients consented and retained to full data completion - ≥80% recruitment rate
Feasibility - Successful Randomization
Time frame: 30 days
Overall proportion of consented patients successfully receiving randomization at the completion of operation divided by the total number of consented patients - ≥80% randomized
Feasibility - POCUS Study completion
Time frame: 30 days
Overall proportion of completed studies divided by expected studies - ≥80% completion
Feasibility - Protocol Adherence
Time frame: 30 days
Overall proportion of patients adequately receiving treatment as defined by the trial protocol divided by the total number of patients enrolled - ≥80% Adherence
Feasibility - Successful Data Collection
Time frame: 30 days
Overall proportion of patients with no absent data points in the database divided by the total number of patients enrolled - ≥80% complete data sets
Feasibility - Contamination rate
Time frame: 30 days
The number of patients crossed over into the opposite arm of the study based on patient or physician motivators divided by the total number of patients enrolled - ≤20% contamination
1 secondary outcome
Feasibility - POCUS image quality
Time frame: 30 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2021.
- Individual participant dataSharing planned: No. As this is a feasibility trial, there are no plans to make individual patient data available to other researchers. The individual patient data may be used as part of a larger randomized controlled trial if the feasibility trial shows the protocol is feasible and safe.
Related trials for Aortic Diseases
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luc Dubois, MD principal investigator
London Health Sciences Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Point of Care Ultrasound (POCUS) in people with Aortic Diseases, run by London Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact John H Landau, MD (519.685.8500 ext. 19438, john.landau@londonhospitals.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility - Recruitment (time frame: 30 days). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2021.